Spasticity Management in Multiple Sclerosis Evidence-Based Management Strategies for Spasticity Treatment in Multiple Sclerosis

Jk, Haselkorn; C, Balsdon Richer; D, Fry Welch; Rm, Herndon; Johnson, Beau; Jw, Little; Miller, '; Jh, Rosenberg; Me, Seidle

doi:10.1080/10790268.2005.11754545

Cited by 43 publications

(28 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than half of the baclofen cohort (55.3%) were subjects with MS. Treatment guidelines for spasticity in MS developed by the Multiple Sclerosis Council for Clinical Practice Guidelines recommend starting pharmacologic treatment for spasticity with either baclofen or tizanidine [7]. Although no preference is offered in this guideline for use of either baclofen or tizanidine in the treatment of spasticity, only 33.4% of subjects were initiated on the latter.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adherence Associated With Oral Medications in the Treatment of Spasticity

Halpern

Gillard

Graham

et al. 2013

PM&R

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Because spasticity can result from a variety of pathologies, treatment guidelines exist for separate conditions [7][8][9][10][11][12][13][14]. Most guidelines are similar in approach to that published in 1993 by Parziale et al [15] for the treatment of spasticity associated with SCI.…”

mentioning

confidence: 99%

Adherence Associated With Oral Medications in the Treatment of Spasticity

Halpern

Gillard

Graham

et al. 2013

PM&R

View full text Add to dashboard Cite

show abstract

“…The extent of spasticity can vary from mild muscle stiffness to severe, uncontrollable muscle spasms that can result in disfigurement, disability and pain. Pharmacological treatment of spasticity is indicated when symptom severity cannot be controlled by rehabilitation strategies, as described in the Multiple Sclerosis Council for Clinical Practice Guidelines (2). Tizanidine, approved by the Food and Drug Administration in 1996, is often used as an antispastic agent when oral treatment is indicated.…”

Section: Introductionmentioning

confidence: 99%

A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients

Henney¹,

Runyan²

2008

International Journal of Clinical Practice

View full text Add to dashboard Cite

There is substantial evidence to show that plasma tizanidine concentrations are linearly related to dose in healthy subjects and patients, although there is a high degree of intersubject variability. The most common adverse events and pharmacodynamic effects are related to plasma concentrations. The clinical implications of the large interpatient variability in plasma tizanidine concentrations and its narrow therapeutic index make it necessary to individualise patient therapy. Practical advice on tizanidine dosing and/or switching between formulations is provided.

show abstract

“…HT settings should control the environmental temperature and humidity, and the water temperature. The use of warm pools may be appropriate for carefully selected individuals but it was not included as a recommendation in the Spasticity Management Guidelines of the MS Council for Clinical Practice Guidelines (MSCCPG) 50 . HT therapeutic elements were used to assist, resist or support movement 49,51 .…”

Section: Discussionmentioning

confidence: 99%

Rehabilitation for Multiple Sclerosis, in Adults (II); Management and Impact on Impairment, Functioning, and Quality of Life: An Overview

Martinez-Assucena¹,

Marnetoft

Rovira

et al. 2010

Crit Rev Phys Rehabil Med

View full text Add to dashboard Cite

Multiple Sclerosis (MS) may lead to different severity and progression of impairment and disability and to dissimilar levels of limitation in activities and participation in different social domains, with impacts on quality of life (QoL) of persons with MS (PwMS). Results have shown that PwMS prioritizing goalsetting may enhance adherence to treatment; that interdisciplinary rehabilitation may prolong PwMS' functional status level, display transient improvement in the aspects of impairment features, increase their participation in activities, and improve their QoL, despite not modifying disease progression; that single rehabilitation packages of comprehensive care components have proven beneficial, such as physiotherapy, enhancing aerobic capacity, strength, pain, mood, mobility, and QoL; occupational therapy, reducing the impact of impairment on QoL, especially fatigue; neuropsychological interventions, such as learning and memory remediation; psychological intervention for depressive disorders; coping, self-management techniques, helping to adjust to disease and disability; speech therapy, improving intelligibility; swallowing techniques, preventing material from entering the airway; clean intermittent self-catheterism, avoiding urinary tract infections; power wheelchairs, enhancing occupational performance and energy conservation. Further Vocational Rehabilitation settings and research are required for more appropriate interventions due to high unemployment rates among PwMS. Comprehensive information should include planning for future independent living and long-term care needs.different body function and body structure impairment, and related terms. The development of each heading was structured in an introduction, aim and results format.A summary summed up results. In the Ph heading there was a common introduction and aim, while results and summary were described under each subheading. CM texts presented a description of CM's features and summary, since no evidence-based results about its effectiveness on MS were found. Refworks was used as reference management to index and cite the references in the text. In this manuscript, medical therapeutic interventions, such as pharmacological and non-pharmacological therapy, and interventions for caregivers have not been included. Original authors' expressions, such as "multidisciplinary RHB", were accepted. I. Rehabilitation planning and interdisciplinary Rehabilitation interventions Rehabilitation planningphysicians' role 14 . In different countries, this function has been assumed by Neurologists. Features of its goals have been described as specific, measurable, achievable, realistic and timed (SMART) 16 . PwMS and their significant others, and multiprofessional teams did not necessarily agree on GS and on expectations as to the amount of improvement and the likelihood of achieving their goals 31 Achieving goals could be measured by means of Goal Attainment Scaling 32 . AimThe aim was to report on the effectiveness of RHBP, applied to PwMS. ResultsThe effectivenes...

show abstract

Spasticity Management in Multiple Sclerosis Evidence-Based Management Strategies for Spasticity Treatment in Multiple Sclerosis

Cited by 43 publications

References 63 publications

Adherence Associated With Oral Medications in the Treatment of Spasticity

Adherence Associated With Oral Medications in the Treatment of Spasticity

A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients

Rehabilitation for Multiple Sclerosis, in Adults (II); Management and Impact on Impairment, Functioning, and Quality of Life: An Overview

Contact Info

Product

Resources

About